Table 4 Susceptibility patterns with respect to age, health seeking and treatment during the malaria epidemic of 2006 in Muleba district, Tanzania (n = 319)
Variable | Number of respondents (%) | P-Value | ||
|---|---|---|---|---|
| Â | Overall | Epidemic area | Non-Epidemic area | Â |
Susceptibility by age group (years) | Â | Â | Â | Â |
   Below 5 | 169 (53) | 116 (50.0) | 53 (60.9) | 0.082 |
   5-19 | 98 (30.7) | 75 (32.3) | 23 (26.4) | 0.308 |
   20-35 | 14 (4.4) | 11 (4.5) | 3 (3.5) | 0.692 |
   36-65 | 30 (9.4) | 25 (10.8) | 5 (5.8) | 0.173 |
   Above 65 | 8 (2.5) | 5 (2.2) | 3 (3.5) | 0.512 |
Source of healthcare services | Â | Â | Â | Â |
   Health facility | 278 (87.2) | 204 (87.9) | 74 (85.1) | 0.506 |
   Drug shop | 27 (8.5) | 19 (8.2) | 8 (9.2) | 0.775 |
   Self treatment using herbs | 10 (3.1) | 7 (3.0) | 3 (3.5) | 0.820 |
Drug used for treatment of malaria | Â | Â | Â | Â |
Sulfadoxine-pyrimethamine | Â | Â | Â | Â |
   Yes | 92 (29) | 74 (31.9) | 18 (21.2) |  |
   No | 225 (71) | 158 (68.1) | 67 (78.8) | 0.063 |
Amodiaquine | Â | Â | Â | Â |
   Yes | 63 (20) | 42 (18.1) | 21 (24.7) |  |
   No | 254 (80.1) | 190 (81.9) | 64 (75.3) | 0.192 |
Antermisinin compounds | Â | Â | Â | Â |
   Yes | 24 (7.6) | 16 (6.9) | 8 (9.4) |  |
   No | 293 (92.4) | 216 (93.1) | 77 (90.6) | 0.456 |
Quinine | Â | Â | Â | Â |
   Yes | 78 (24.6) | 25 (25.4) | 19 (22.4) |  |
   No | 239 (75.4) | 173 (74.6) | 66 (77.7) | 0.591 |
Chloroquine | Â | Â | Â | Â |
   Yes | 15 (4.7) | 11 (4.7) | 4 (4.7) |  |
   No | 302 (95.3) | 221 (95.3) | 81 (95.3) | 1.000 |
Don't know | Â | Â | Â | Â |
   Yes | 63 (79.8) | 38 (84.4) | 25 (73.5) |  |
   No | 16 (20.3) | 7 (15.6) | 9 (26.5) | 0.236 |